Position of the Transparency Council – Voydeya (danicopan)

At its meeting on 31 March 2025, the Transparency Council adopted position No. 38/2025 on the evaluation of the drug Voydeya (danicopan) within the framework of the drug program B.96. “Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 D59.5)”

Publication of the position >>